Global Markets Direct’s, ‘Paralysis – Pipeline Review, H2 2015′, provides an overview of the Paralysis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Paralysis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Paralysis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Paralysis
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Paralysis and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Paralysis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Paralysis pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Paralysis
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Paralysis pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Paralysis Overview 6
Therapeutics Development 7
Pipeline Products for Paralysis - Overview 7
Pipeline Products for Paralysis - Comparative Analysis 8
Paralysis - Therapeutics under Development by Companies 9
Paralysis - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Unknown Stage Products 12
Paralysis - Products under Development by Companies 13
Paralysis - Companies Involved in Therapeutics Development 14
Asahi Kasei Pharma Corp. 14
Immunome Inc. 15
Marathon Pharmaceuticals, LLC 16
Neuralstem, Inc. 17
Ultragenyx Pharmaceutical Inc. 18
Paralysis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
BNZ-1321 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
elcatonin - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
flunarizine hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Monoclonal Antibody Conjugates for Paralysis - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NSI-566 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
REM-1086 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
UX-007 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Paralysis - Recent Pipeline Updates 38
Paralysis - Dormant Projects 48
Paralysis - Discontinued Products 49
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables

Number of Products under Development for Paralysis, H2 2015 7
Number of Products under Development for Paralysis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Comparative Analysis by Unknown Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Paralysis - Pipeline by Asahi Kasei Pharma Corp., H2 2015 14
Paralysis - Pipeline by Immunome Inc., H2 2015 15
Paralysis - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015 16
Paralysis - Pipeline by Neuralstem, Inc., H2 2015 17
Paralysis - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015 18
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Stage and Target, H2 2015 21
Number of Products by Stage and Mechanism of Action, H2 2015 23
Number of Products by Stage and Route of Administration, H2 2015 25
Number of Products by Stage and Molecule Type, H2 2015 27
Paralysis Therapeutics - Recent Pipeline Updates, H2 2015 38
Paralysis - Dormant Projects, H2 2015 48
Paralysis - Discontinued Products, H2 2015 49

List of Figures

Number of Products under Development for Paralysis, H2 2015 7
Number of Products under Development for Paralysis - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Assessment by Monotherapy Products, H2 2015 19
Number of Products by Top 10 Targets, H2 2015 20
Number of Products by Stage and Top 10 Targets, H2 2015 20
Number of Products by Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 22
Number of Products by Top 10 Routes of Administration, H2 2015 24
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 24
Number of Products by Top 10 Molecule Types, H2 2015 26
Number of Products by Stage and Top 10 Molecule Types, H2 2015 26